Search research articles
Contact Us
Filters
Showing results (261-270 of 387) with videos related to
Page
of 39
Sort By:
Frontiers in Immunology
|
March 11, 2022
C10orf99/GPR15L Regulates Proinflammatory Response of Keratinocytes and Barrier Formation of the Skin
Teruki Dainichi, Yuri Nakano, Hiromi Doi, et al.
American Journal of Clinical Dermatology
|
August 18, 2021
Integrated Safety Analysis of Abrocitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis From the Phase II and Phase III Clinical Trial Program
Eric L Simpson, Jonathan I Silverberg, Audrey Nosbaum, et al.
The Journal of Allergy and Clinical Immunology
|
August 17, 2019
Crisaborole and atopic dermatitis skin biomarkers: An intrapatient randomized trial
Robert Bissonnette, Ana B Pavel, Aisleen Diaz, et al.
Nature Communications
|
May 8, 2021
Selective sweep for an enhancer involucrin allele identifies skin barrier adaptation out of Africa
Mary Elizabeth Mathyer, Erin A Brettmann, Alina D Schmidt, et al.
RMD Open
|
February 8, 2023
Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis
Gerd R Burmester, Stanley B Cohen, Kevin L Winthrop, et al.
The Journal of Allergy and Clinical Immunology
|
December 29, 2023
Efficacy and safety of rademikibart (CBP-201), a next-generation mAb targeting IL-4Rα, in adults with moderate to severe atopic dermatitis: A phase 2 randomized trial (CBP-201-WW001)
Jonathan I Silverberg, Bruce Strober, Brian Feinstein, et al.
Journal of the American Academy of Dermatology
|
February 3, 2025
Tape-strip profiling identifies unique immune and lipid dysregulation in patients with seborrheic dermatitis
Benjamin Ungar, Meredith Manson, Madeline Kim, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
November 15, 2025
Safety of upadacitinib in atopic dermatitis in randomized clinical trials across 6 years
Christopher G Bunick, Alan D Irvine, Jonathan I Silverberg, et al.
The Journal of Allergy and Clinical Immunology. in Practice
|
November 5, 2021
COVID-19 Symptoms Are Attenuated in Moderate-to-Severe Atopic Dermatitis Patients Treated with Dupilumab
Benjamin Ungar, Jacob W Glickman, Alexandra K Golant, et al.
Allergy
|
August 8, 2024
Alopecia areata exhibits cutaneous and systemic OX40 activation across atopic backgrounds
Madeline Kim, Ester Del Duca, Dante Dahabreh, et al.
Page
of 39
Search research articles
Search
Showing results (261-270 of 387) with videos related to
Sort By:
Page
of 39
Frontiers in Immunology
|
March 11, 2022
C10orf99/GPR15L Regulates Proinflammatory Response of Keratinocytes and Barrier Formation of the Skin
Teruki Dainichi, Yuri Nakano, Hiromi Doi, et al.
American Journal of Clinical Dermatology
|
August 18, 2021
Integrated Safety Analysis of Abrocitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis From the Phase II and Phase III Clinical Trial Program
Eric L Simpson, Jonathan I Silverberg, Audrey Nosbaum, et al.
The Journal of Allergy and Clinical Immunology
|
August 17, 2019
Crisaborole and atopic dermatitis skin biomarkers: An intrapatient randomized trial
Robert Bissonnette, Ana B Pavel, Aisleen Diaz, et al.
Nature Communications
|
May 8, 2021
Selective sweep for an enhancer involucrin allele identifies skin barrier adaptation out of Africa
Mary Elizabeth Mathyer, Erin A Brettmann, Alina D Schmidt, et al.
RMD Open
|
February 8, 2023
Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis
Gerd R Burmester, Stanley B Cohen, Kevin L Winthrop, et al.
The Journal of Allergy and Clinical Immunology
|
December 29, 2023
Efficacy and safety of rademikibart (CBP-201), a next-generation mAb targeting IL-4Rα, in adults with moderate to severe atopic dermatitis: A phase 2 randomized trial (CBP-201-WW001)
Jonathan I Silverberg, Bruce Strober, Brian Feinstein, et al.
Journal of the American Academy of Dermatology
|
February 3, 2025
Tape-strip profiling identifies unique immune and lipid dysregulation in patients with seborrheic dermatitis
Benjamin Ungar, Meredith Manson, Madeline Kim, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
November 15, 2025
Safety of upadacitinib in atopic dermatitis in randomized clinical trials across 6 years
Christopher G Bunick, Alan D Irvine, Jonathan I Silverberg, et al.
The Journal of Allergy and Clinical Immunology. in Practice
|
November 5, 2021
COVID-19 Symptoms Are Attenuated in Moderate-to-Severe Atopic Dermatitis Patients Treated with Dupilumab
Benjamin Ungar, Jacob W Glickman, Alexandra K Golant, et al.
Allergy
|
August 8, 2024
Alopecia areata exhibits cutaneous and systemic OX40 activation across atopic backgrounds
Madeline Kim, Ester Del Duca, Dante Dahabreh, et al.
Page
of 39